Hip implant studies seek cause of high failure rate in UK
This article was originally published in Clinica
In the next few weeks, orthopaedic surgeons in the UK will begin examining nearly 5,000 patients who have been given the 3M Capital Hip implant following government warnings that it could fail prematurely.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.